General Information of Drug (ID: DM5O0CM)

Drug Name
L-772,405 Drug Info
Synonyms L-772405; L 772405
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
9847194
TTD Drug ID
DM5O0CM

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting 5-HT 1B receptor (HTR1B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [3]
Eletriptan DMW649X Migraine 8A80 Approved [4]
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [4]
Frovatriptan DM7RE8P Migraine 8A80 Approved [4]
Fluphenazine DMIT8LX Psychotic disorder 6A20-6A25 Approved [4]
Naratriptan DMO50U2 Headache 8A80-8A84 Approved [5]
Prolixin decanoate DMMJ1IS Schizophrenia 6A20 Approved [4]
Eltoprazine DMW6C81 Attention deficit hyperactivity disorder 6A05.Z Phase 3 [6]
NXN-188 DMMBAIH Migraine 8A80 Phase 2 [7]
[N-methyl-3H(3)]AZ-10419369 DMSCV02 Mood disorder 6A60-6E23 Phase 1 [8]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 1D receptor (HTR1D)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [9]
Eletriptan DMW649X Migraine 8A80 Approved [4]
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [4]
Frovatriptan DM7RE8P Migraine 8A80 Approved [4]
Sumatriptan DMVYXR8 Cluster headache 8A81.0 Approved [10]
Rizatriptan DMDJMA3 Migraine 8A80 Approved [11]
Almogran DM7I64Z Migraine 8A80 Approved [12]
Neu-P11 DMIQDFW Alzheimer disease 8A20 Phase 2 [13]
FKB01MD DM2O7NM N. A. N. A. Phase 2 [14]
NXN-188 DMMBAIH Migraine 8A80 Phase 2 [7]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 1A receptor (HTR1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Trazodone DMK1GBJ Depression 6A70-6A7Z Approved [4]
Buspirone DMBS632 Anxiety disorder 6B00-6B0Z Approved [15]
OPC-34712 DMHG57U Major depressive disorder 6A70.3 Approved [16]
Vilazodone DM4LECQ Major depressive disorder 6A70.3 Approved [17]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [18]
Gepirone DMGX5Q0 Major depressive disorder 6A70.3 Approved [19]
TERTATOLOL DM2L3D5 Hypertension BA00-BA04 Approved [20]
Urapidil DMD59GI Hypertension BA00-BA04 Approved [21]
Treximet DMU54QB Migraine 8A80 Approved [22]
CM-2395 DMASPWR Schizophrenia 6A20 Phase 3 [23]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1A receptor (HTR1A) TTSQIFT 5HT1A_HUMAN Agonist [2]
5-HT 1B receptor (HTR1B) TTK8CXU 5HT1B_HUMAN Agonist [2]
5-HT 1D receptor (HTR1D) TT6MSOK 5HT1D_HUMAN Antagonist [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 16).
2 3-[3-(Piperidin-1-yl)propyl]indoles as highly selective h5-HT(1D) receptor agonists. J Med Chem. 1999 Dec 2;42(24):4981-5001.
3 Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5 Triptans in pregnancy. Ther Drug Monit. 2008 Feb;30(1):5-9.
6 Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
7 Company report (NeurAxon)
8 5-HT1B and other related serotonergic proteins are altered in APPswe mutation. Neurosci Lett. 2015 May 6;594:137-43.
9 Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
10 Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
11 An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210.
12 Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75.
13 Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
14 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
15 Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
16 Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
17 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
18 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
19 Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
20 Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
21 Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
22 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
23 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)